Wang Zhuo, Shen Shu-Hong, Tang Yan-Jing, Xue Hui-Liang, Hu Wen-Ting, Pan Ci, Tang Jing-Yan, Gu Long-Jun, Chen Jing
Department of Hematology/Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Nov;21(11):1073-1078. doi: 10.7499/j.issn.1008-8830.2019.11.004.
To study the clinical effect of the SCMC APL-2010 regimen in the treatment of acute promyelocytic leukemia (APL) in children.
A retrospective analysis was performed for the clinical data of 44 children with APL who received treatment with the SCMC APL-2010 regimen between April 2010 and July 2016. The Kaplan-Meier survival analysis was used to evaluate event-free survival (EFS) rate and overall survival (OS) rate.
Of the 44 children with APL, 42 (95%) achieved a complete remission (CR) after one course of treatment and 1 achieved CR after two courses of treatment, with an overall CR rate of 98%. The 9-year EFS and OS rates were 96%±3% and 97.7%±2.2% respectively. As for adverse events, 41 (93%) had infection, 29 (66%) had granulocyte reduction, 12 (27%, 1 died) had differentiation syndrome, 16 (36%) had liver dysfunction, 12 (27%) had adverse gastrointestinal reactions, and 7 (16%) had QT prolongation, 1 (2%) had orchitis, and no secondary neoplasm was observed.
Children with APL receiving the SCMC APL-2010 regimen have a good prognosis and can achieve a long-term survival, while treatment-related infection is commonly seen.
研究SCMC APL - 2010方案治疗儿童急性早幼粒细胞白血病（APL）的临床疗效。
对2010年4月至2016年7月期间接受SCMC APL - 2010方案治疗的44例儿童APL患者的临床资料进行回顾性分析。采用Kaplan - Meier生存分析评估无事件生存率（EFS）和总生存率（OS）。
44例儿童APL患者中，42例（95%）在一个疗程后达到完全缓解（CR），1例在两个疗程后达到CR，总CR率为98%。9年EFS率和OS率分别为96%±3%和97.7%±2.2%。不良事件方面，41例（93%）发生感染，29例（66%）出现粒细胞减少，12例（27%，1例死亡）发生分化综合征，16例（36%）出现肝功能障碍，12例（27%）出现胃肠道不良反应，7例（16%）出现QT间期延长，1例（2%）发生睾丸炎，未观察到继发性肿瘤。
接受SCMC APL - 2010方案治疗的儿童APL患者预后良好，可实现长期生存，但治疗相关感染较为常见。
